home / stock / auph / auph news


AUPH News and Press, Aurinia Pharmaceuticals Inc From 02/28/22

Stock Information

Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com

Menu

AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...

AUPH - EVBG, IRNT and NTRB among mid-day movers

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...

AUPH - Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2021 Results - Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2021 Earnings Conference Call February 28, 2022 08:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conf...

AUPH - IntriCon, NeuroSense top healthcare gainers; Aurinia, Lexicon lead losers' pack

Gainers: IntriCon (NASDAQ:IIN) +37%. NeuroSense Therapeutics (NASDAQ:NRSN) +28%. Homology Medicines (NASDAQ:FIXX) +17%. CorMedix (NASDAQ:CRMD) +14%. Reata Pharmaceuticals (NASDAQ:RETA) +13%. Losers: Aurinia Pharmaceuticals (NASDAQ:AUPH) -29%. Lexicon Pharmac...

AUPH - Aurinia falls after lower-than-expected sales outlook for 2022

Despite beating Street forecasts with its Q4 2021 financials, Aurinia Pharmaceuticals (NASDAQ:AUPH) has lost ~20% in the pre-market Monday after the commercial-stage biopharmaceutical company disappointed investors with its sales outlook for 2022. Aurinia (AUPH), which commerci...

AUPH - Aurinia Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $23.4M beats by $1.57M

Aurinia Pharma press release (NASDAQ:AUPH): Q4 GAAP EPS of -$0.25 beats by $0.02. Revenue of $23.4M (-53.2% Y/Y) beats by $1.57M. For further details see: Aurinia Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $23.4M beats by $1.57M

AUPH - Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates

$23.4 million in net revenue for the fourth quarter 2021 (60% increase from third quarter) and $45.6 million in net revenue for full year 2021 2021 readout of strong results from AURORA 2 continuation study fuels momentum for year two of launch Cash and cash equivalent...

AUPH - Aurinia Pharma Q4 2021 Earnings Preview

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q4 earnings results on Monday, February 28th, before market open. The consensus EPS Estimate is -$0.27 and the consensus Revenue Estimate is $21.83M (-56.4% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 dow...

AUPH - Notable earnings before Monday's open

AUPH, AZRE, BFLY, BRK.B, CVEO, CWEN, DEA, DQ, FREY, GLP, ITRI, JLL, KOS, LINC, MRSN, NLSN, PRTY, RETA, RIDE, TGNA, VRS, VTRS, XPEL, XRAY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

AUPH - Aurinia Pharma gains after CEO comments on sales outlook

Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials for Q4 2021 at the end of February.    Canada-based Aurinia (NASDAQ:AUPH) markets LUPK...

AUPH - Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its fourth quarter and year end 2021 financial results on Monday, February 28, 2021, before markets open. Aurinia’s management team will host a conference call/webcast a...

Previous 10 Next 10